CA3035806A1 - Lysine specific histone demethylase-1 inhibitors and uses therefor - Google Patents

Lysine specific histone demethylase-1 inhibitors and uses therefor Download PDF

Info

Publication number
CA3035806A1
CA3035806A1 CA3035806A CA3035806A CA3035806A1 CA 3035806 A1 CA3035806 A1 CA 3035806A1 CA 3035806 A CA3035806 A CA 3035806A CA 3035806 A CA3035806 A CA 3035806A CA 3035806 A1 CA3035806 A1 CA 3035806A1
Authority
CA
Canada
Prior art keywords
lsd1
isolated
proteinaceous molecule
cell
residues
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3035806A
Other languages
English (en)
French (fr)
Inventor
Sudha RAO
Peter MILBURN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Canberra
Original Assignee
University of Canberra
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2016903602A external-priority patent/AU2016903602A0/en
Application filed by University of Canberra filed Critical University of Canberra
Publication of CA3035806A1 publication Critical patent/CA3035806A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/13—Tumour cells, irrespective of tissue of origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C12N9/0083—Miscellaneous (1.14.99)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
    • C12Y114/99—Miscellaneous (1.14.99)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA3035806A 2016-09-07 2017-09-07 Lysine specific histone demethylase-1 inhibitors and uses therefor Pending CA3035806A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2016903602A AU2016903602A0 (en) 2016-09-07 Inhibitors and uses therefor
AU2016903602 2016-09-07
PCT/AU2017/050969 WO2018045422A1 (en) 2016-09-07 2017-09-07 Lysine specific histone demethylase-1 inhibitors and uses therefor

Publications (1)

Publication Number Publication Date
CA3035806A1 true CA3035806A1 (en) 2018-03-15

Family

ID=61561256

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3035806A Pending CA3035806A1 (en) 2016-09-07 2017-09-07 Lysine specific histone demethylase-1 inhibitors and uses therefor

Country Status (8)

Country Link
US (1) US20220040280A1 (cg-RX-API-DMAC10.html)
EP (1) EP3509627A4 (cg-RX-API-DMAC10.html)
JP (1) JP2019534317A (cg-RX-API-DMAC10.html)
CN (1) CN110312522A (cg-RX-API-DMAC10.html)
AU (1) AU2017323868A1 (cg-RX-API-DMAC10.html)
CA (1) CA3035806A1 (cg-RX-API-DMAC10.html)
SG (1) SG11201901624RA (cg-RX-API-DMAC10.html)
WO (1) WO2018045422A1 (cg-RX-API-DMAC10.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110142068A (zh) * 2019-06-12 2019-08-20 杭州华得森生物技术有限公司 一种上皮间质混合型循环肿瘤细胞检测试剂盒及方法

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102095104B1 (ko) * 2018-04-24 2020-04-23 서울대학교산학협력단 PKCα-LSD1-NFκB 경로를 표적으로 하는 염증반응 조절제 스크리닝 방법용도
EP3636284A1 (en) * 2018-10-11 2020-04-15 NBE Therapeutics AG Binding protein-toxin conjugates comprising anthracyclines, and use thereof in immune-oncological applications
CA3149964A1 (en) * 2019-09-03 2021-03-11 Michelle Wykes Methods and agents for determining patient status
CN112326961B (zh) * 2020-10-30 2021-08-06 福州迈新生物技术开发有限公司 一种非小细胞肺癌中pd-l1阳性肿瘤细胞比例的分析方法和存储设备
EP4419093A1 (en) * 2021-10-20 2024-08-28 Queen Mary University of London Sequential treatments and biomarkers to reverse resistance to kinase inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7741086B2 (en) * 2004-12-16 2010-06-22 President And Fellows Of Harvard College Histone demethylation mediated by the nuclear amine oxidase homolog LSD1
WO2007006581A2 (en) * 2005-07-13 2007-01-18 Universitätsklinikum Freiburg Targeting lsd1 for use in identifying and/or scoring prostate cancer and for controlling anrogen receptor-dependent gene expression
WO2012009475A1 (en) * 2010-07-14 2012-01-19 Oregon Health & Science University Methods of treating cancer with inhibition of lysine-specific demethylase 1
US20120108500A1 (en) * 2010-10-07 2012-05-03 Naoki Sakane Compositions and Methods for Modulating Immunodeficiency Virus Transcription
EP3789405A1 (en) * 2012-10-12 2021-03-10 The General Hospital Corporation Transcription activator-like effector (tale) - lysine-specific demethylase 1 (lsd1) fusion proteins
SG11201510369WA (en) * 2013-06-25 2016-01-28 Univ Canberra Methods and compositions for modulating cancer stem cells
US9186391B2 (en) * 2013-08-29 2015-11-17 Musc Foundation For Research Development Cyclic peptide inhibitors of lysine-specific demethylase 1
AU2015309686B2 (en) * 2014-08-25 2020-05-14 Epiaxis Therapeutics Pty Ltd Compositions for modulating cancer stem cells and uses therefor
KR20180099768A (ko) * 2015-12-30 2018-09-05 노파르티스 아게 증진된 효능을 갖는 면역 이펙터 세포 요법

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110142068A (zh) * 2019-06-12 2019-08-20 杭州华得森生物技术有限公司 一种上皮间质混合型循环肿瘤细胞检测试剂盒及方法
CN110142068B (zh) * 2019-06-12 2024-02-02 杭州华得森生物技术有限公司 一种上皮间质混合型循环肿瘤细胞检测试剂盒及方法

Also Published As

Publication number Publication date
SG11201901624RA (en) 2019-03-28
US20220040280A1 (en) 2022-02-10
EP3509627A1 (en) 2019-07-17
CN110312522A (zh) 2019-10-08
EP3509627A4 (en) 2020-05-06
JP2019534317A (ja) 2019-11-28
AU2017323868A1 (en) 2019-03-21
WO2018045422A1 (en) 2018-03-15

Similar Documents

Publication Publication Date Title
US20220040280A1 (en) Inhibitors and uses thereof
CA2916533C (en) Methods and compositions for modulating cancer stem cells
AU2015309686B2 (en) Compositions for modulating cancer stem cells and uses therefor
CN112204047A (zh) Pd-l1结合黏合素及与其相关的用途
US20200353036A1 (en) Peptide-polynucleotide-hyaluronic acid nanoparticles and methods for polynucleotide transfection
US20220073880A1 (en) Natural killer cells
US10736892B2 (en) Stem cell modulation II
JP2021510538A (ja) タンパク質性分子およびその使用
CA3204415A1 (en) Modified mir-135, conjugated form thereof, and uses of same
CA3026154A1 (en) Mobilizing agents and uses therefor
WO2023077188A1 (en) Proteinaceous molecules and uses therefor
WO2024151501A1 (en) Novel imidazopyrimidine compound and uses thereof
US20250120956A1 (en) Azole Compounds for Enhancing Telomerase Reverse Transcriptase (TERT) Expression
WO2022218997A1 (en) Novel universal vaccine presenting system
CN116546998A (zh) 葡萄糖调节化合物、其组合物和其用途

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20211213